


The New Era of Gene Expression Profiling with MammaPrint® + Blueprint®

Confidently and quickly establish a personalized treatment plan for your patients*, ranging from neoadjuvant chemotherapy decisions to extended endocrine therapy, by utilizing MammaPrint + Blueprint results obtained within six days.^{1†}



ESBC = Early-stage breast cancer

† Agendia is committed to delivering results in less than 10 business days, and results are provided within 6 business days for the majority of cases.

* Women 18 years or older with early-stage breast cancer

Results should be taken in the context of other relevant clinico-pathological factors and standard practice of medicine.

Analyzing 150 genes, MammaPrint + Blueprint provide comprehensive treatment considerations as early as initial consultation.

Increased precision in CT treatment response⁶

Identify patients who may:

- Consider or forgo neoadjuvant CT
- Consider or forgo adjuvant CT
- Consider Neoadjuvant CT + Immunotherapy

Identify tumor subtype for precise treatment planning⁶

Go beyond traditional IHC/FISH with Blueprint to:

- Identify aggressive ER+ Basal tumors that behave like TNBC
- Improve precision of predicting survival outcomes
- Improve precision in determining pCR rates
- Identify HER2 tumors

Optimize endocrine treatment duration⁶

Identify patients who may:

- Consider neoadjuvant ET
- Consider 5 years of ET and may consider safely discontinuing <5 years in event of ET intolerance
- Consider a full 5 years of ET
- Consider extending ET for an additional 5 years

Quick and precise answers

Together, MammaPrint + Blueprint:

- Analyze 150 genes, incremental to pathology
- Deliver quick results, available within six days^{**1}
- Provide results that are independent of age, menopausal status, lymph node status, race, and other clinical factors

** Agendia is committed to delivering results in less than 10 business days, and results are provided within 6 business days for the majority of cases.

6 Extensive peer reviewed publications and studies utilizing MammaPrint + Blueprint have observed benefit from treatment as described in the Care Pathway. See Care Pathway for full list of references.

